Singapore markets closed
  • Straits Times Index

    3,217.41
    +10.42 (+0.32%)
     
  • Nikkei

    31,857.62
    -14.90 (-0.05%)
     
  • Hang Seng

    17,809.66
    +436.63 (+2.51%)
     
  • FTSE 100

    7,608.08
    +6.23 (+0.08%)
     
  • Bitcoin USD

    27,150.15
    +209.21 (+0.78%)
     
  • CMC Crypto 200

    579.66
    +0.90 (+0.15%)
     
  • S&P 500

    4,288.05
    -11.65 (-0.27%)
     
  • Dow

    33,507.50
    -158.84 (-0.47%)
     
  • Nasdaq

    13,219.32
    +18.05 (+0.14%)
     
  • Gold

    1,864.60
    -14.00 (-0.75%)
     
  • Crude Oil

    90.77
    -0.94 (-1.02%)
     
  • 10-Yr Bond

    4.5730
    -0.0240 (-0.52%)
     
  • FTSE Bursa Malaysia

    1,424.17
    -15.94 (-1.11%)
     
  • Jakarta Composite Index

    6,939.89
    +2.06 (+0.03%)
     
  • PSE Index

    6,321.24
    -64.28 (-1.01%)
     

Is CRISPR Therapeutics Stock a Buy Now?

Is CRISPR Therapeutics Stock a Buy Now?

A year ago, CRISPR Therapeutics' (NASDAQ: CRSP) stock was trading for $46 per share. As of Tuesday afternoon, the biotech stock was at $64. While other investors have begun to catch on to the upside of the company, it's still a clinical-stage biopharmaceutical company -- that is, one with no marketed therapies yet.